In endurance athletes with intense joint loading, cartilage metabolism (degradation of type II collagen) is enhanced compared with non-athletes and non-endurance athletes. Recently, we have revealed that glucosamine, a functional food, exerts a protective action on cartilage metabolism in not only osteoarthritis patients but also endurance athletes (such as soccer players) by suppressing the degradation of type II collagen. In this review, to demonstrate these findings, the following topics will be presented: 1. Biomarkers for cartilage metabolism; 2. Evaluation of cartilage metabolism in endurance athletes by using biomarkers for cartilage metabolism; 3. Chondroprotective action of glucosamine on endurance athletes.
Introduction
The severity and frequency of joint loading are principal factors for the development of joint destruction, which is characterized by the articular cartilage damage. Actually, excessive motion and load on the joint cause the articular cartilage damage 1)-4) . Thus, sports with repetitive impact and torsional loading on the joints enhance the risk of articular cartilage degeneration, and result in the clinical symptoms of osteoarthritis 4) . The pathological process of osteoarthritis leads to the degradation and functional loss of joint cartilage. Notably, the early changes of the cartilage metabolism can be detected before the appearance of morphological changes of cartilage 2) . Thus, a number of biomarkers with reliability and sensitivity have been developed as indicators of cartilage metabolism in subjects with joint disorders 5) .
Nutritional supplements, including glucosamine, chondroitin and collagen, are used for joint health to treat or prevent sports-related cartilage injuries (i.e., osteoarthritis) in athletes 6)-8) . Among these, glucosamine, an amino monosaccharide, has been widely used to treat osteoarthritis in humans 9) -12) . Recently, we have revealed that glucosamine exhibits a protective action on cartilage metabolism in not only osteoarthritis patients but also endurance athletes by suppressing the degradation of type II collagen, as evidenced by the reduced level of type II collagen degradation markers 13 ) -15) . Thus, in this review, to demonstrate these findings, the following topics will be presented: 1. Biomarkers for cartilage metabolism; 2. Evaluation of cartilage metabolism in endurance athletes by using biomarkers for cartilage metabolism; 3. Chondroprotective action of glucosamine on endurance athletes.
Biomarkers for cartilage metabolism
Type II collagen is the major components of cartilage 16) , and the fragments of type II collagen are utilized as biomarkers for cartilage metabolism ( Figure-1) . A C-terminal telopeptide (CTX-II) is cleaved during degradation of type II collagen 17) , whereas a neo-epitope (C2C) is cleaved at the C terminus of the 3/4 piece of degraded type II collagen 18) . Thus, both CTX-II and C2C are used as markers for type II collagen degradation. In contrast, a C-terminal type II procollagen peptide (CPII) is present in newly formed type II procollagen and cleaved during processing of synthesized type II procollagen; thus, CPII can be used as a marker for type II collagen synthesis 19) . Moreover, type I collagen is the major components of bone; thus, deoxypyridinoline (Dpyr), a crosslink product of type I collagen and cross-linked N-terminal telopeptides of type I collagen (NTx) are used as markers for type I collagen degradation in bone (bone resorption) 5) .
Effect of endurance exercise on cartilage and bone metabolism
It has been reported that sports and exercise affect cartilage and bone metabolism. OʼKane et al. compared the urine levels of type II collagen degradation marker CTX-II and type I collagen degradation marker NTx among non-athlete controls, cross-country runners, swimmers and crew members 3) . The results indicated that the levels of CTX-II and NTx are increased in the cross-country runners and crew members compared with nonathletes and swimmers, suggesting that cartilage and bone metabolism (type II and type I collagen degradation) is increased by endurance exercise with intense joint loading, such as cross county and boat racing. Thus, to test this hypothesis, we evaluated the cartilage and bone metabolism in collegiate athletes belonging to various sports clubs (soccer, tennis, triathlon, squash, swimming, volleyball, kendo, judo, gymnastics, basketball, handball, baseball, long-distance, throwing-event, jumping, sprint and futsal) by analyzing the urine levels of type II collagen degradation maker CTX-II and synthesis marker CPII, and type I collagen degradation marker NTx, and compared with those of non-athlete controls 20) . Table-1 shows the background of enrolled nonathlete controls and athletes (all males). First, NTx levels were compared among athletes of various sporting events. The results indicated that NTx levels were significantly higher in soccer, volleyball, basketball and handball players than non-athlete controls ( Figure-2) .
Furthermore, the levels of CTX-II and CPII were compared between non-athlete controls and athletes of various sporting events. Similar to the levels of NTx, CTX-II levels were significantly higher in soccer, volleyball and handball players than nonathlete controls (Figure-3A ). In contrast, CPII levels were significantly higher in squash players and long-distance runners than non-athlete controls ( Figure-3B ). Base on the levels of CTX-II and CPII, the CTX-II/CPII ratios were calculated and compared between non-athlete controls and athletes of various sporting events. The results indicated that the CTX-II/CPII ratios were higher in soccer, volleyball, basketball and handball players than non-athlete controls ( Figure-3C ), suggesting that type II collagen degradation is relatively enhanced compared with type II collagen synthesis in these athletes.
The similar changes of NTx ( 5) , their levels are changed in parallel within the body.
Chondroprotective action of glucosamine on endurance athletes
Next, we evaluated the chondroprotective action of glucosamine on endurance exercise. Glucosamine is an amino monosaccharide with an amino group, and functions as a component of glycosaminoglycans (such as hyaluronic acid and chondroitin sulfate) 21) ( Figure-5 ). Figure-6 shows the synthetic pathway of glycosaminoglycans in our body 22) ;
glucose is converted into glucosamine with the addition of amino group from glutamine, and further converted into N-acetyl-glucosamine and N-acetyl-galactosamine. Then, these glucosaminederivatives are coupled with uronic acid to form glycosaminoglycans (such as hyaluronic acid, keratin sulfate and chondroitin sulfate) present in the articular cartilage, skin and other tissues. Importantly, glucosamine supplement is efficiently absorbed from the intestine, distributed to various tissues and used as a constituent of glycosaminoglycans. Thus, glucosamine is widely utilized as a functional food with a chondroprotective action to treat human diseases such as osteoarthritis as a precursor of glycosaminoglycans 9)-12)
. Furthermore, we have demonstrated that glucosamine suppresses the activation of neutrophils 23) , synovial cells 24) and intestinal epithelial cells 25) , endothelial cells 26) , and inhibits adjuvant arthritis 27) , colitis 28) and atherosclerosis 29) in animal models.
Thus, glucosamine expectantly exhibits antiinflammatory actions. So, we evaluated the effect of glucosamine on cartilage metabolism using collegiate soccer players with intense joint loading 30) . In this study, 41 soccer players (mean age, 20.2 ± 1.1 years; 20 subjects in the placebo group, 21 subjects in the glucosamine group) were recruited. Subjects were randomly assigned to receive a 2,000 mg glucosaminecontaining supplement (glucosamine group) or a 
Figure-3 Comparison of the urine levels of CTX-II and CPII, and CTX-II/CPII ratio between non-athlete controls and various sports athletes
Urine levels of CTX-II (A) and CPII (B) in non-athlete controls and various sports athletes (shown in Table-1) were measured by ELISA and corrected by urinary creatinine (Cr). Moreover, the ratios of type II collagen degradation to synthesis (CTX-II/CPII) in non-athlete controls and various sports athletes were calculated (C), using the levels of CTX-II and CPII shown in Figures 3A and B . Data represent the mean ± SD. Values are compared between non-athletes (10 subjects) and various sports athletes (5~11 subjects) by one-way ANOVA with Bonferroni post hoc test. ) placebo containing only a vehicle (placebo group). All subjects were instructed to take the test supplement or placebo once a day within 30 min after exercise for 16 weeks. Table-2 presents the baseline characteristics of these subjects, including age, physiological characteristics (body height, body weight and body mass index) and levels of biomarkers for type I collagen metabolism (NTx) and type II collagen metabolism (CTX-II, C2C and CPII). There were no significant differences in these parameters between the placebo and glucosamine groups at the baseline.
The effect of test supplement on cartilage metabolism was evaluated using these subjects at weeks 0 and 16 during the intervention. Notably, urine CTX-II level significantly decreased in the glucosamine group but not in the placebo group after the intervention for 16 weeks (p < 0.05); moreover, CTX-II levels were significantly decreased in the glucosamine group compared with that in the placebo group after the intervention for 16 weeks (p < 0.05) (Figure-7A ). Similarly, serum C2C level significantly decreased in the glucosamine group but not in the placebo group after the intervention for 16 weeks (p < 0.05), although C2C levels were not significantly different between the placebo and glucosamine groups after the intervention for 16 weeks (Figure-7B ). In contrast, urine CPII levels were not significantly different between weeks 0 and 16 during the intervention in the placebo or glucosamine group, and between the placebo and glucosamine groups after the intervention for 16 weeks (Figure-7C) . Similarly, urine NTx levels were not significantly different between weeks 0 and 16 during the intervention in the placebo or glucosamine group, and between the placebo and glucosamine groups after the intervention for 16 weeks (Figure-7D ).
Discussion and Conclusion
Cartilage biomarkers can be used to evaluate the pathophysiological conditions of joint disorders 5) . The biomarkers are basically derived form the constituents of cartilage, such as aggrecan, chondroitin sulfate and collagens 5) 16) . Among these constituents, type II collagen is a major constituent of articular cartilage, and the catabolism and anabolism of articular type II collagen are involved in the pathological conditions of joint disorders; thus, the components of type II collagen are recognized as the most important biomarkers for cartilage metabolism and joint disorders (such as osteoarthritis) 31) . In this review, I presented the data on the cartilage and bone metabolism in college athletes belonging to various sports clubs, which were analyzed based on the levels of type II
Figure-4 Correlation analysis of bone and cartilage metabolism markers
Correlations between CTX-II and NTx (A), CPII and NTx (B), and CPII and CTX-II (C) were analyzed among enrolled subjects (n = 170, non-athletes controls and various sports athletes, shown in Table- 
Figure-7
Effect of glucosamine administration on the biomarkers for type II collagen degradation, type II collagen synthesis and type I collagen degradation in soccer players
Soccer players (shown in Table- 2) were orally administered with a placebo or glucosamine-containing supplement (2,000 mg/day for 16 weeks), and urine and serum samples were collected at weeks 0 and 16 during the glucosamine administration. Urine CTX-II (A), serum C2C (B), urine CPII (C) and urine NTx (D) were measured by ELISA, and the levels of urine markers were corrected by urinary creatinine (Cr). Data are the mean ± SD of 20 subjects in the placebo group and 21 subjects in the glucosamine group. Values were compared between weeks 0 and 16 in the placebo or glucosamine groups, and among multiple groups (such as the placebo and glucosamine groups at weeks 0 and 16 during the intervention) by two-way ANOVA with Tukey post hoc test. . The results indicated that cartilage metabolism (type II collagen degradation) as well as bone metabolism (type I collagen degradation) is enhanced in endurance exercise associated with jumping action, such as soccer, volleyball, basketball and handball.
Further, I presented the data on the chondroprotective action of glucosamine on endurance athletes, especially soccer players with intense joint loading 30) . The results revealed that urine CTX-II level significantly decreased in the glucosamine group but not in the placebo group after the intervention for 16 weeks (p < 0.05) (Figure-7A ). Similarly, serum C2C level significantly decreased in the glucosamine group but not in the placebo group after the intervention for 16 weeks (p < 0.05) (Figure-7B ). In contrast, the levels of urine CPII as well as urine NTx were not significantly changed even after the intervention in both the placebo and glucosamine group ( Figure-7C and D) . Thus, glucosamine administration (2,000 mg /day for 16 weeks) significantly reduces the levels of CTX-II and C2C but not CPII and NTx, confirming that glucosamine exerts a chondroprotective action in endurance athletes (soccer players) by suppressing type II collagen degradation (as assessed by CTX-II and C2C, type II collagen degradation markers).
It has been reported that glucosamine suppresses the production of matrix metalloproteinase (MMP)-13, a major type II collagen-degradaing enzyme, from chondrocytes and synoviocytes in vitro 32) 33) and reduces the serum level of MMP-3 in sera of patients with rheumatoid arthritis 34) . Based on these findings, it is interesting to speculate that glucosamine inhibits MMP production, thereby suppressing type II collagen degradation (as evidenced by the reduction of CTX-II and C2C levels) in vivo. In contrast, glucosamine administration did not essentially affect the levels of CPII as well as NTx, suggesting no effect of glucosamine administration on the levels of type II collagen synthesis (CPII) and type I collagen degradation (NTx) in soccer players. Importantly, glucosamine has been reported to enhance the expression of type II collagen in chondrocytes in vitro 33) ; however, the increase of type II collagen synthesis (as evaluated by CPII) could not be detected in soccer players (Figure-7C ). This is probably due to the fact that type II collagen synthesis (as evaluated by CPII) was slightly increased in soccer players compared with non-athlete controls ( Figure-3B) 14) 20) , although the increase is not significant; thus, the CPII level cannot be further enhanced by glucosamine administration. In summary, type II collagen degradation is relatively increased compared with type II collagen synthesis in endurance athletes. Glucosamine exhibits a chondroprotective action in endurance athletes (such as soccer players) by preventing type II collagen degradation but maintaining type II collagen synthesis.
